Functional outcomes from a phase II study of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (CREATE Study).

Trial Profile

Functional outcomes from a phase II study of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (CREATE Study).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs AZD 9056 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms CREATE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Oct 2012 Results published in Annals of the Rheumatic Diseases.
    • 20 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top